Interview with Physician from First HydroPICC Use
April 10, 2019
Earlier this year, Access Vascular’s HydroPICC device was first used in patients at Riverside Medical Center in Kankakee, IL. HydroPICC represents a new option for clinicians to address catheter-related thrombosis, and upcoming field evaluations of the device will seek to establish our new hydrogel material platform as the preferred option for venous access. Read about Dr. Arun Jagannathan’s experience using HydroPICC and his thoughts on the impact that the material could have across venous access.
Access Vascular Publishes Results of Head-to-Head In Vitro Tip Occlusion Study
April 3, 2019
Access Vascular is pleased to announce the publication of head-to-head in vitro tip occlusion results comparing HydroPICC with the market leading catheter, PowerPICC (Becton Dickinson). In in vitro blood flow loop testing, HydroPICC exhibited a complete reduction in thrombotic occlusion rate when compared to the PowerPICC catheter. Read the full results here.
Access Vascular Hosts Podcast on Difficult Venous Access
March 25, 2019
Access Vascular had the opportunity to host Dr. Jeffrey Chick and Dr. Arun Jagannathan at the company’s booth at the Society of Interventional Radiology 2019 conference for an engaging discussion on difficult venous access. The podcast was hosted by BackTable podcast, a premier source for information on tools and techniques for interventional radiologists. Listen to the podcast here.
Access Vascular Begins First Clinical Use of HydroPICC
February 8, 2019
Riverside Medical Center became the first hospital to implant Access Vascular’s HydroPICC peripherally inserted central catheter (PICC). The device is designed from a novel biomaterial created to address the most common and costly complications plaguing the global venous access market.
Dr. Arun Jagannathan, one of the attending interventional radiologists who placed the initial devices, shared his enthusiasm for the novel device, noting, "Chronically ill patients require frequent and often long-term intravenous access which invariably results in destruction and eventual depletion of their vascular access options over time. This catheter represents the most significant advance in venous access technology that I've experienced since I started practicing over ten years ago. Due to the device’s lubriciousness, it may allow health care providers to mitigate venous access depletion."
Access Vascular Publishes In Vitro and In Vivo Results
September 15, 2018
Access Vascular has published the results of in-vitro and in-vivo studies of HydroPICC. HydroPICC showed an up to 30x reduction in thrombus accumulation versus polyurethane catheters and minimal formation of a fibrin sheath. Read the full results here.
FDA Clears AVI’s HydroPICC
February 22, 2018
MassDevice: Access Vascular, a medical device company reinventing venous access using proprietary material technology designed to reduce thrombus accumulation, announced today that the Company has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its lead product.
AVI raises $3.7M to Support HydroPICC
August 29, 2017
Access Vascular has announced US$3.7m in funding from individual investors and angelMD, an investment platform and marketplace connecting innovative medical start-ups, physicians, investors and industry partners. This financing will help support submission of a 510(k) application later this year, for Access Vascular’s lead product, the HydroPICC, a superior peripherally-inserted central catheter.